 Jason Hoppe
Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 21 | 2023 | 794 | 4.570 |
Why?
| | Emergency Service, Hospital | 31 | 2023 | 1865 | 3.160 |
Why?
| | Prescription Drug Monitoring Programs | 5 | 2023 | 11 | 2.400 |
Why?
| | Opioid-Related Disorders | 8 | 2022 | 417 | 2.030 |
Why?
| | Practice Patterns, Physicians' | 13 | 2023 | 1200 | 1.780 |
Why?
| | Buprenorphine | 5 | 2022 | 136 | 1.740 |
Why?
| | Back Pain | 4 | 2023 | 44 | 1.530 |
Why?
| | Pain | 4 | 2023 | 735 | 1.150 |
Why?
| | Prescription Drugs | 5 | 2017 | 113 | 1.140 |
Why?
| | Decision Support Systems, Clinical | 3 | 2023 | 178 | 1.050 |
Why?
| | Naloxone | 2 | 2021 | 98 | 0.880 |
Why?
| | Drug Overdose | 5 | 2021 | 294 | 0.820 |
Why?
| | Emergency Medicine | 2 | 2022 | 238 | 0.790 |
Why?
| | Narcotic Antagonists | 6 | 2022 | 136 | 0.760 |
Why?
| | Pain Management | 3 | 2017 | 294 | 0.610 |
Why?
| | Drug Prescriptions | 4 | 2023 | 248 | 0.580 |
Why?
| | Attitude of Health Personnel | 3 | 2020 | 992 | 0.560 |
Why?
| | Drug Monitoring | 2 | 2017 | 187 | 0.560 |
Why?
| | Substance Abuse Detection | 2 | 2014 | 63 | 0.510 |
Why?
| | Controlled Substances | 1 | 2014 | 2 | 0.510 |
Why?
| | Pharmacies | 1 | 2014 | 31 | 0.490 |
Why?
| | Physicians | 2 | 2020 | 794 | 0.490 |
Why?
| | Opiate Substitution Treatment | 4 | 2022 | 96 | 0.470 |
Why?
| | Prescriptions | 2 | 2023 | 63 | 0.460 |
Why?
| | Drug-Seeking Behavior | 1 | 2013 | 22 | 0.460 |
Why?
| | Cannabinoids | 3 | 2020 | 115 | 0.420 |
Why?
| | Pharmacists | 1 | 2014 | 238 | 0.410 |
Why?
| | Humans | 42 | 2023 | 118974 | 0.390 |
Why?
| | Retrospective Studies | 14 | 2023 | 12978 | 0.370 |
Why?
| | Patient Discharge | 1 | 2016 | 796 | 0.360 |
Why?
| | Adult | 20 | 2022 | 31512 | 0.330 |
Why?
| | Abdominal Pain | 3 | 2019 | 133 | 0.320 |
Why?
| | Marijuana Abuse | 2 | 2020 | 209 | 0.300 |
Why?
| | Drug Packaging | 2 | 2017 | 44 | 0.290 |
Why?
| | Male | 23 | 2022 | 57801 | 0.270 |
Why?
| | Cross-Sectional Studies | 8 | 2021 | 4552 | 0.270 |
Why?
| | Middle Aged | 13 | 2020 | 27617 | 0.250 |
Why?
| | Female | 21 | 2020 | 61565 | 0.250 |
Why?
| | Academic Medical Centers | 2 | 2017 | 422 | 0.240 |
Why?
| | Vomiting | 3 | 2020 | 123 | 0.230 |
Why?
| | Delivery of Health Care | 2 | 2021 | 867 | 0.230 |
Why?
| | Capsaicin | 2 | 2020 | 26 | 0.220 |
Why?
| | Electronic Health Records | 2 | 2023 | 829 | 0.220 |
Why?
| | Prescription Drug Misuse | 1 | 2022 | 38 | 0.200 |
Why?
| | Young Adult | 8 | 2019 | 10793 | 0.200 |
Why?
| | Quality Indicators, Health Care | 1 | 2023 | 295 | 0.190 |
Why?
| | Patient Handoff | 1 | 2020 | 27 | 0.180 |
Why?
| | Certification | 1 | 2020 | 99 | 0.180 |
Why?
| | Antiemetics | 1 | 2019 | 34 | 0.180 |
Why?
| | Ketorolac | 1 | 2019 | 18 | 0.170 |
Why?
| | Haloperidol | 1 | 2019 | 36 | 0.170 |
Why?
| | Infection Control | 1 | 2020 | 135 | 0.170 |
Why?
| | Social Work | 1 | 2020 | 69 | 0.170 |
Why?
| | Drug Storage | 2 | 2017 | 59 | 0.170 |
Why?
| | Poisoning | 2 | 2017 | 109 | 0.170 |
Why?
| | Benzodiazepines | 2 | 2017 | 122 | 0.170 |
Why?
| | United States | 7 | 2021 | 12555 | 0.170 |
Why?
| | Risk Factors | 4 | 2023 | 9000 | 0.160 |
Why?
| | Referral and Consultation | 2 | 2021 | 648 | 0.160 |
Why?
| | Automobile Driving | 1 | 2020 | 128 | 0.160 |
Why?
| | Acetaminophen | 2 | 2011 | 244 | 0.160 |
Why?
| | Accidents, Home | 1 | 2017 | 32 | 0.150 |
Why?
| | Medical Staff, Hospital | 1 | 2017 | 76 | 0.150 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 304 | 0.140 |
Why?
| | Marijuana Smoking | 1 | 2019 | 220 | 0.140 |
Why?
| | Logistic Models | 3 | 2017 | 1901 | 0.140 |
Why?
| | Pharmacovigilance | 1 | 2015 | 13 | 0.140 |
Why?
| | Drug Utilization | 2 | 2014 | 169 | 0.140 |
Why?
| | Inappropriate Prescribing | 1 | 2016 | 51 | 0.140 |
Why?
| | Odds Ratio | 2 | 2017 | 996 | 0.130 |
Why?
| | Codeine | 1 | 2015 | 6 | 0.130 |
Why?
| | Pandemics | 2 | 2021 | 1355 | 0.130 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 69 | 0.130 |
Why?
| | Hydrocodone | 1 | 2015 | 15 | 0.130 |
Why?
| | Cohort Studies | 2 | 2016 | 5116 | 0.130 |
Why?
| | Aged | 8 | 2020 | 19657 | 0.130 |
Why?
| | Prospective Studies | 3 | 2023 | 6471 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 348 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
| | Medication Reconciliation | 1 | 2015 | 25 | 0.130 |
Why?
| | Guideline Adherence | 2 | 2017 | 523 | 0.130 |
Why?
| | Self Report | 2 | 2020 | 699 | 0.130 |
Why?
| | Medication Errors | 1 | 2015 | 92 | 0.130 |
Why?
| | Oxycodone | 1 | 2015 | 45 | 0.130 |
Why?
| | Urban Population | 1 | 2017 | 409 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2021 | 781 | 0.130 |
Why?
| | Indazoles | 1 | 2014 | 60 | 0.120 |
Why?
| | Antipsychotic Agents | 2 | 2019 | 193 | 0.110 |
Why?
| | Adolescent | 6 | 2019 | 18480 | 0.110 |
Why?
| | Chronic Pain | 1 | 2016 | 211 | 0.110 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 245 | 0.110 |
Why?
| | Aged, 80 and over | 4 | 2019 | 6561 | 0.110 |
Why?
| | Respiratory Insufficiency | 1 | 2016 | 290 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 399 | 0.110 |
Why?
| | Cooperative Behavior | 1 | 2014 | 408 | 0.100 |
Why?
| | Hospitalization | 1 | 2020 | 1785 | 0.100 |
Why?
| | Colorado | 3 | 2019 | 4196 | 0.100 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 9 | 0.100 |
Why?
| | Fractures, Bone | 1 | 2015 | 380 | 0.090 |
Why?
| | Curriculum | 1 | 2016 | 910 | 0.090 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2011 | 116 | 0.090 |
Why?
| | Acetylcysteine | 1 | 2010 | 148 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1440 | 0.090 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 86 | 0.080 |
Why?
| | Cardiovascular System | 1 | 2009 | 127 | 0.080 |
Why?
| | Antidotes | 1 | 2009 | 126 | 0.080 |
Why?
| | Prescription Drug Overuse | 2 | 2017 | 12 | 0.070 |
Why?
| | Consensus | 2 | 2021 | 534 | 0.070 |
Why?
| | Nausea | 2 | 2019 | 107 | 0.070 |
Why?
| | Length of Stay | 2 | 2020 | 1032 | 0.060 |
Why?
| | Medical History Taking | 2 | 2015 | 120 | 0.060 |
Why?
| | Nonprescription Drugs | 2 | 2015 | 67 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2019 | 3171 | 0.050 |
Why?
| | Wisconsin | 1 | 2020 | 91 | 0.050 |
Why?
| | Community Health Workers | 1 | 2020 | 49 | 0.040 |
Why?
| | Organizational Innovation | 1 | 2020 | 138 | 0.040 |
Why?
| | Administration, Topical | 1 | 2019 | 141 | 0.040 |
Why?
| | Data Collection | 1 | 2022 | 658 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 344 | 0.040 |
Why?
| | Risk Assessment | 2 | 2017 | 3057 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.040 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 265 | 0.040 |
Why?
| | Health Transition | 1 | 2016 | 7 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 119 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 4708 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 525 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 387 | 0.030 |
Why?
| | Plant Preparations | 1 | 2015 | 23 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 212 | 0.030 |
Why?
| | Analgesics | 1 | 2016 | 159 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2016 | 262 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 546 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 104 | 0.030 |
Why?
| | Vitamins | 1 | 2015 | 158 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 505 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 1293 | 0.030 |
Why?
| | Qualitative Research | 1 | 2017 | 953 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1474 | 0.030 |
Why?
| | Eating | 1 | 2014 | 369 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2874 | 0.030 |
Why?
| | Program Evaluation | 1 | 2016 | 845 | 0.030 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2015 | 467 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 322 | 0.020 |
Why?
| | Decision Making | 1 | 2017 | 809 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 42 | 0.020 |
Why?
| | Aging | 1 | 2020 | 1670 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 210 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 2995 | 0.020 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 25 | 0.020 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 20 | 0.020 |
Why?
| | Aripiprazole | 1 | 2009 | 18 | 0.020 |
Why?
| | Risperidone | 1 | 2009 | 27 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 380 | 0.020 |
Why?
| | Thiazoles | 1 | 2009 | 121 | 0.020 |
Why?
| | Quality Improvement | 1 | 2016 | 963 | 0.020 |
Why?
| | Safety | 1 | 2010 | 304 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 965 | 0.020 |
Why?
| | Quinolones | 1 | 2009 | 98 | 0.020 |
Why?
| | Child | 2 | 2017 | 19129 | 0.020 |
Why?
| | Anaphylaxis | 1 | 2010 | 146 | 0.020 |
Why?
| | Piperazines | 1 | 2009 | 316 | 0.020 |
Why?
| | Internship and Residency | 1 | 2016 | 1001 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1945 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2009 | 693 | 0.020 |
Why?
| | Infant | 1 | 2017 | 8293 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 9491 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 3443 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2010 | 9342 | 0.010 |
Why?
|
|
Hoppe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|